| |
Number of resistant isolates/total isolates (proportion) within the year
|
|---|
|
Microorganisms
|
2001
|
2002
|
2003
|
2004
|
2005
|
Total
|
|---|
|
Gram-positive
| | | | | | |
|
Staphylococcus epidermidis
| | | | | | |
|
Oxacillin*
|
0/15 (0)
|
6/15 (40)
|
7/26 (26.9)
| | |
13/56 (23.2)
|
|
Gentamicin
|
2/15 (13.3)
|
1/15 (6.7)
|
1/26 (3.8)
|
0/26 (0)
|
9/52 (17.3)
|
13/134 (9.7)
|
|
Vancomycin
|
0/15 (0)
|
0/15 (0)
|
0/26(0)
|
0/26 (0)
|
0/52 (0)
|
0/134 (0)
|
|
Penicillin
| | | |
13/26 (50)
|
40/52 (76.9)
|
53/78 (67.9)
|
|
Staphylococcus aureus
| | | | | | |
|
Oxacillin*
|
0/6 (0)
|
5/9 (55.6)
|
0/14 (0)
| | |
5/29 (17.2)
|
|
Gentamicin
|
1/6 (16.7)
|
1/9 (11.1)
|
0/14 (0)
|
3/21 (14.3)
|
1/18 (5.6)
|
6/68 (8.8)
|
|
Vancomycin
|
0/6 (0)
|
0/9 (0)
|
0/14 (0)
|
0/21 (0)
|
0/18 (0)
|
0/68 (0)
|
|
Penicillin
| | | |
14/21 (66.7)
|
13/18 (72.2)
|
27/39 (69)
|
|
Streptococcus viridans
| | | | | | |
|
Penicillin
| | |
0/1 (0)
| | |
0/1 (0)
|
|
Vancomycin
| | |
0/1 (0)
| | |
0/1 (0)
|
|
Gram-negative
| | | | | | |
|
Escherichia coli
| | | | | | |
|
Trimethoprim-sulfamethoxazole
|
8/20 (40)
|
6/17 (35.2)
|
6/22 (27.2)
|
6/22 (27.2)
|
6/27 (22.2)
|
32/108 (29.6)
|
|
Amikacin
|
8/20 (40)
|
4/17 (23.5)
|
1/22 (4.5)
|
0/22 (0)
|
6/27 (22.2)
|
19/108 (17.6)
|
|
Gentamicin
|
2/20 (10)
|
4/17 (23.5)
|
0/22 (0)
|
0/22 (0)
|
2/27 (7.4)
|
8/108 (7.4)
|
|
Ampicillin
|
3/20 (15)
|
0/17 (0)
|
6/22 (27.2)
|
8/22 (36.3)
|
10/27 (37.0)
|
27/108 (25.0)
|
|
Cefuroxime
|
0/20 (0)
|
0/17 (0)
|
2/22 (9.1)
|
1/22 (4.5)
|
6/27 (22.2)
|
9/108 (8.3)
|
|
Pseudomonas aeruginosa
| | | | | | |
|
Amikacin
|
0/2 (0)
|
0/3 (0)
|
0/4 (0)
|
0/11 (0)
|
3/9 (33.3)
|
3/29 (10.3)
|
|
Ceftazidime
|
0/2 (0)
|
0/3 (0)
|
0/4 (0)
|
2/11 (18.2)
|
2/9 (22.2)
|
4/29 (13.8)
|
|
Ciprofloxacin
|
1/2 (50)
|
0/3 (0)
|
0/4 (0)
|
4/11 (36.4)
|
3/9 (33.3)
|
8/29 (27.6)
|
|
Imipenem
|
0/2 (0)
|
0/3 (0)
|
0/4 (0)
|
0/11 (0)
|
1/9 (11.1)
|
1/29 (3.4)
|
|
Acinetobacter baumanii
| | | | | | |
|
Amikacin
| | |
0/3 (0)
|
1/2 (50)
|
0/1 (0)
|
1/6 (16.7)
|
|
Gentamicin
| | |
0/3 (0)
|
0/2 (0)
|
0/1 (0)
|
0/6 (0)
|
|
Ceftazidime
| | |
3/3 (100)
|
1/2 (50)
|
0/1 (0)
|
4/6 (66.7)
|
|
Ciprofloxacin
| | |
3/3 (100)
|
2/2 (100)
|
0/1 (0)
|
5/6 (83.3)
|
|
Imipenem
| | |
0/3 (0)
|
0/2 (0)
|
1/1 (100)
|
0/6 (0)
|
|
Klebsiella pneumoniae
| | | | | | |
|
Ceftazidime
| |
0/1 (0)
| | |
0/2 (0)
|
0/3 (0)
|
|
Ciprofloxacin
| |
0/1 (0)
| | |
1/2 (50)
|
1/3 (33.3)
|
|
Meropenem
| |
0/1 (0)
| | |
0/2 (0)
|
0/3 (0)
|
|
Cefepime
| |
0/1 (0)
| | |
0/2 (0)
|
0/3 (0)
|
|
Cefoxitin
| |
1/1 (100)
| | |
0/2 (0)
|
1/3 (33.3)
|
|
Tobramycin
| |
0/1 (0)
| | |
0/2 (0)
|
0/3 (0)
|
- * Oxacillin discs were not available for antimicrobial testing during the period 16/05/2003 – 15/05/2005
